Bridgeway Capital Management’s Candel Therapeutics CADL Stock Holding History

Bridgeway Capital Management’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75,100	Closed	-$368K	–	1245
2026 Q1	$368K	Buy	75,100 +20,000	+36%	+$109K	0.01%	886
2025 Q4	$311K	Hold	55,100	–	–	0.01%	924
2025 Q3	$281K	Hold	55,100	–	–	0.01%	944
2025 Q2	$279K	Buy	+55,100	New	+$284K	0.01%	882
2025 Q1	–	Sell	-77,195	Closed	-$670K	–	1185
2024 Q4	$670K	Sell	77,195 -3,400	-4%	-$20.1K	0.02%	756
2024 Q3	$559K	Hold	80,595	–	–	0.01%	839
2024 Q2	$500K	Sell	80,595 -2,000	-2%	-$15K	0.01%	860
2024 Q1	$131K	Sell	82,595 -50,000	-38%	-$74.2K	﹤0.01%	1178
2023 Q4	$195K	Hold	132,595	–	–	﹤0.01%	1139
2023 Q3	$123K	Hold	132,595	–	–	﹤0.01%	1188
2023 Q2	$167K	Sell	132,595 -105	-0.1%	-$155	﹤0.01%	1175
2023 Q1	$182K	Hold	132,700	–	–	﹤0.01%	1121
2022 Q4	$238K	Hold	132,700	–	–	0.01%	1046
2022 Q3	$417K	Hold	132,700	–	–	0.01%	939
2022 Q2	$430K	Buy	132,700 +57,700	+77%	+$231K	0.01%	913
2022 Q1	$382K	Buy	+75,000	New	+$372K	0.01%	1010

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bridgeway Capital Management's CADL Position: Q2 2026 in Review

Bridgeway Capital Management sold out of Candel Therapeutics (CADL) in Q2 2026, closing a stake of 75,100 shares — an estimated $368K sold.

Bridgeway Capital Management first reported a position in CADL in Q1 2022 and held it in 16 quarters. The position peaked at $670K in Q4 2024. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

Bridgeway Capital Management reported no remaining Candel Therapeutics position as of Q2 2026 after selling out during the quarter.
Bridgeway Capital Management sold 75,100 Candel Therapeutics shares in Q2 2026, an estimated $368K.
Bridgeway Capital Management first reported a position in Candel Therapeutics in Q1 2022 and held it in 16 quarters.
Bridgeway Capital Management's Candel Therapeutics position peaked at $670K in Q4 2024.
138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.